The RMC-9805 study demonstrated a 30% objective response rate and 80% disease control rate in PDAC patients. How significant are these findings in the context of the current treatment landscape for advanced pancreatic cancer?

Given that G12D is a common mutation in PDAC, how promising is the selective targeting approach of RMC-9805 in potentially improving outcomes for these patients compared to broader therapies?

The study reports that RMC-9805 was generally well tolerated, with mostly mild adverse events. How important is this favorable safety profile for patients who often undergo aggressive treatments, and how might it impact patient quality of life?

With the data indicating tolerability at higher doses, could you discuss the potential of RMC-9805 as part of a combination therapy in PDAC, especially for patients with a high burden of disease?

The trial hasn’t reached a maximum tolerated dose. How might this finding influence the dosing strategy in future studies, and could it provide flexibility in tailoring treatments for individual patients?

The reported 80% disease control rate suggests that many patients achieve stable disease. Can you elaborate on how this metric might translate to longer progression-free survival in PDAC?

With preliminary data showing encouraging tumor regression, what insights can you provide on the potential durability of response for patients treated with RMC-9805?

Looking ahead, what are the key milestones Revolution Medicines should target in developing RMC-9805 as a viable treatment for PDAC, and what challenges might lie ahead in securing regulatory approval for this patient group?